Cadila Healthcare arm recalls 21,240 bottles of diabetes drug in US

Viona Pharmaceuticals Inc is recalling over 21,000 bottles of metformin hydrochloride extended-release tablets manufactured by Ahmedabad-based Cadila Healthcare, the latest enforcement report of the US Food and Drug Administration (USFDA) said.
Representative Image
Representative Image

New Delhi

Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. 
Viona Pharmaceuticals Inc is recalling 21,240 bottles of metformin hydrochloride extended-release tablets, USP 750 mg, on account of "CGMP Deviations: FDA analysis detected n-nitrosodimethylamine (NDMA) levels in excess of the acceptable daily intake limit", the report by the US health regulator said. 
The voluntary ongoing nationwide recall in the US is a class-II recall, it added. 
As per USFDA, a class-II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 
NDMA is classified as a probable human carcinogen based on results from laboratory tests. It is a known environmental contaminant and found in water and foods, including meats, dairy products and vegetables. 
Viona Pharmaceuticals Inc is a wholly-owned indirect subsidiary of Cadila Healthcare.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Related Stories

No stories found.
DT next
www.dtnext.in